Alemanha - alemão - myHealthbox

accord healthcare limited - paricalcitol - injektionslösung - 5 mikrogramm/ml - calciumhomöostase, andere nebenschilddrüsen-antagonisten - paricalcitol ist indiziert zur prävention und therapie eines sekundären hyperparathyreoidismus bei patienten mit chronischem nierenversagen, die hämodialysepflichtig sind.

Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

accord healthcare b.v. (8182087) - bisoprololfumarat (ph.eur.) - filmtablette - teil 1 - filmtablette; bisoprololfumarat (ph.eur.) (23549) 10 milligramm

Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

accord healthcare b.v. (8182087) - bisoprololfumarat (ph.eur.) - filmtablette - teil 1 - filmtablette; bisoprololfumarat (ph.eur.) (23549) 5 milligramm

Alemanha - alemão - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

accord healthcare b.v. (8182087) - bisoprololfumarat (ph.eur.) - filmtablette - teil 1 - filmtablette; bisoprololfumarat (ph.eur.) (23549) 2,5 milligramm

União Europeia - alemão - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

União Europeia - alemão - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

União Europeia - alemão - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastische mittel - azacitidine accord ist indiziert für die behandlung von erwachsenen patienten, die nicht förderfähig sind für die hämatopoetische stammzelltransplantation (hszt) mit:- intermediate-2 und high-risk myelodysplastischen syndromen (mds) nach dem international prognostic scoring system (ipss),- chronische myelomonocytic leukämie (cmml) mit 10-29 % knochenmark blasten ohne myeloproliferative störung,- akute myeloische leukämie (aml) mit 20-30 % blasten und multi-lineage dysplasie, nach angaben der world health organisation (who) - klassifikation,- aml mit >30% knochenmark blasten nach der who-klassifikation.

União Europeia - alemão - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare ltd - ondansetron hydrochlorid - ondansetron

Áustria - alemão - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - bendamustin hydrochlorid monohydrat -